Evidence map›Paper›PMID 42415230›Full record

Trial reportOncoimmunology2026

Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.

Lorenzo Falchi, Martin Hutchings, David Tybor, Junhua Yu, Abualbishr Alshreef, Anthony Wang, Kavita Sail, Zhijie Ding, Alex Mutebi, Poliana Patah and 4 more

Abstract readComparative StudyClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lorenzo FalchiMemorial Sloan-Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1531-3838
Martin HutchingsRigshospitalet and University of Copenhagen, Copenhagen, Denmark.
David TyborAbbVie, North Chicago, IL, USA.
Junhua YuAbbVie, North Chicago, IL, USA.
Abualbishr AlshreefAbbVie, North Chicago, IL, USA.
Anthony WangAbbVie, North Chicago, IL, USA.
Kavita SailAbbVie, North Chicago, IL, USA.
Zhijie DingGenmab US, Inc, Plainsboro, NJ, USA.
Alex MutebiGenmab US, Inc, Plainsboro, NJ, USA.
Poliana PatahAbbVie, North Chicago, IL, USA.
Nisha KishoreAbbVie, North Chicago, IL, USA.
Ali RanaGenmab US, Inc, Plainsboro, NJ, USA.
Elena FavaroGenmab, Copenhagen, Denmark.
Kim LintonThe Christie NHS Foundation Trust, Division of Cancer Sciences, The University of Manchester, Manchester, UK.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Patients with relapsed/refractory follicular lymphoma (R/R FL) often experience multiple disease recurrences with progressively shorter duration of remission. Chemoimmunotherapy (CIT) is commonly used for R/R FL in second-line and later settings but is not curative; novel, improved treatments are needed. Epcoritamab, a CD3 × CD20 bispecific antibody, is approved as monotherapy for R/R FL after ≥ 2 lines of therapy (LOTs) and combined with lenalidomide and rituximab (R

Indexed as

Antibodies, BispecificAntineoplastic Combined Chemotherapy ProtocolsLenalidomideLymphoma, FollicularNeoplasm Recurrence, LocalRituximabAdultAgedDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedTreatment OutcomeAntibodies, BispecificLenalidomideRituximabchemoimmunotherapyCOTA electronic health recordsEPCORE NHL-2epcoritamablenalidomideRelapsed/refractory follicular lymphomarituximab

Identifiers

PMID42415230
PMCPMC13349012

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.